Tag: Immune mediated adverse reactions

The FDA has fully approved Keytruda, a Merck anti-PD-1 medication, for use in a small number of adult and paediatric patients with advanced MSI-H or mismatch repair deficient solid tumours.

The US Food and Drug Administration (FDA) has fully approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours, as determined by an…

Back to top

Registration Form


This will close in 0 seconds

This will close in 0 seconds

WhatsApp Join Telegram